Detail akcie Aclaris Therap online

Business Summary: Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing novel small and large molecule product candidates for immuno-inflammatory diseases. Its proprietary KINect drug discovery platform coupled with its integrated discovery approach to small and large molecules enables the Company to identify and advance product candidates. It provides contract research services to third parties enabled by its early-stage research and development expertise. The contract research segment is engaged in the provision of laboratory services. Its product candidate pipeline includes Bosakitug (ATI-045), ATI-2138 and ATI-052. The Bosakitug (ATI-045) is an investigational, novel, humanized anti-Thymic stromal lymphopoietin (TSLP) monoclonal antibody that specifically binds to human TSLP, blocking its interaction with the receptor complex and disrupting signal transduction. Its other investigational product candidate is Lepzacitinib (ATI-1777).
Financial Summary: BRIEF: For the three months ended 31 March 2026, Aclaris Therapeutics Inc revenues increased 37% to $2M. Net loss increased 31% to $19.8M. Revenues reflect Licensing increase of 44% to $1.5M, Contract research increase of 21% to $537K. Higher net loss reflects Research and Development - gross increase of 50% to $11.2M (expense), Interest Income decrease of 30% to $1.5M (income), Professional and legal fees increase of 41% to $1.6M (expense).